100% coverage of all exons and significant introns of 50 stomach cancer related genes. Stomocan has minimal sample requirement, covers stomach cancer related molecular targeted/chemotherapy drugs and clinical trials, includes MSI testing which prompts stomach cancer prognosis, provides guidance to immunotherapies (PD-1/PD-L1), and prompts hereditary risks.
100% coverage of all exons and significant introns of 139 lung cancer related genes. Minimal sample requirement. Covers 67 molecular-targeted/chemo drugs and current clinical trials related to lung cancer. Pulmocan is minimally-invasive, supports dynamic monitoring of disease progression, prompts discovery of drug resistance which allows timely adjustments of treatment plans.